Search clinical trials for: Debio 1450

Total 6633 results

Debiopharm International SA

Completed

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Bacterial Infections

United States
Debiopharm International SA

Completed

Study of Debio 1450 for Bacterial Skin Infections

Bacterial Infections

United States
Debiopharm International SA

Completed

Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

Healthy

United Kingdom
Debiopharm International SA

Completed

A Single Dose Study of Debio 1450 in Healthy Subjects

Bacterial Infections

United States
Debiopharm International SA

Completed

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

Bone Diseases, Infectious

United States
Debiopharm International SA
Caris Life Sciences; Optimal Research (Just In Time sites)

Terminated

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Solid Tumor

United States, Spain, Austria, Czechia, Denmark, Russian Federation, United Kingdom, Greece, Norway, Korea, Republic of, France, Taiwan, Netherlands, Bulgaria, Finland, Ukraine, Australia, Brazil, Croatia, Philippines, Poland, Rom... and more
Debiopharm International SA

Completed

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Neoplasms | Lymphoma | Cancer | Solid Tumors

France
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck KGaA, Darmstadt, Germany

Completed

PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants

Healthy

United Kingdom
Debiopharm International SA

Recruiting

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Switzerland
Debiopharm International SA

Completed

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Lymphoma | Cancer | Solid Tumors | Malignancy

United States
Debiopharm International SA

Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Hepatitis C

Romania, Italy, Belgium, Germany, Hungary, Taiwan, Spain, Australia, Hong Kong, Thailand, France, United States, United Kingdom, Turkey, Argentina, Russian Federation, India, Korea, Republic of, Vietnam, Poland, Mexico, Canada
Debiopharm International SA

Completed

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Neoplasms | Carcinoma, Non-Small-Cell Lung

Canada, Poland, Romania
Debiopharm International SA

Recruiting

Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Netherlands, Spain
Debiopharm International SA

Completed

A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects

Healthy Participants

United Kingdom
Debiopharm International SA

Recruiting

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

Central Precocious Puberty

United States
Debiopharm International SA

Terminated

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Solid Tumors

France
University Hospital, Tours

Completed

Study of Hemodynamic Conditions Measured During Hepatectomy (DEBIFOIE)

Liver Dysfunction | Circulatory; Change

France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Romania, Spain, Switzerland, Netherlands, Poland, Por...
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital

Active, not recruiting

Cash Benefits and Reproductive/Perinatal Health

Pregnancy Related | Miscarriage | Maternal Care Patterns

United States
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital; Cambridge Health Alliance

Active, not recruiting

Effect of Cash Benefits on Health Care Utilization

Health Care Utilization

United States
Debiopharm International SA

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Astrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Spain, United States, Switzerland
Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Head and Neck Cancer

Taiwan, United States, Korea, Republic of, Spain, Belgium
Debiopharm International SA

Completed

Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial

Squamous Cell Carcinoma of the Head and Neck

France, Switzerland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
Debiopharm International SA

Completed

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106)

Solid Tumor

United States, Spain, France
Debiopharm International SA
Parexel

Completed

A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Chronic Hepatitis C

Spain, Belgium, Germany, Romania, France, Poland, Italy
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Debiopharm International SA

Recruiting

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Small Cell Lung Cancer Recurrent

United States, Spain
Tang-Du Hospital

Unknown

Effect of Degranulation Needle With Different Diameters on the Rate Good Embryo in IVF

Embryo

China
Cytokinetics
Astellas Pharma Global Development, Inc.

Completed

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States, Canada
Memorial Sloan Kettering Cancer Center
Debiopharm International SA

Completed

A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

Breast Cancer

United States
Debiopharm International SA

Completed

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Chronic Hepatitis C

United States
Population Health Research Institute

Completed

REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) (RECREATE Pilot)

Hyperglycemia | Myocardial Infarction | Cardiovascular Diseases

Argentina, Canada, India
Novartis Pharmaceuticals

Terminated

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Asthma

Germany, Belgium, South Africa, United States, Russian Federation, France, Slovakia, Spain, Thailand, Czechia, Greece, Argentina, Peru, United Kingdom, Bulgaria, Turkey, Hungary, Vietnam, Philippines, Colombia, Chile
National Cancer Institute (NCI)

Terminated

HGS-ETR2 to Treat Children With Solid Tumors

Osteosarcoma | Neuroblastoma | Rhabdomyosarcoma | Ewing's Sarcoma

United States
NeuroBo Pharmaceuticals Inc.

Completed

Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

Hypercholesterolemia
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III... and other conditions
Christian von Buchwald
Bispebjerg Hospital

Recruiting

NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP

Asthma | Obstructive Sleep Apnea | Chronic Rhinosinusitis (Diagnosis) | Nasal Polyps | Inflammatory Disease | Airway Disease | Concomitant Disease

Denmark
University of Southampton
Blue California

Active, not recruiting

Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr) (TaxEr)

Inflammation | Aging | Influenza | Antioxidative Stress | Cold

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

Neoplasms | Anemia
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
SecuraBio

Completed

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 (DDI)

Healthy

United States
Debiopharm International SA
Syneos Health

Terminated

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] (HALO)

Non-small Cell Lung Cancer

Spain, France, United Kingdom
Hartford Hospital
Gilead Sciences

Completed

The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

Arrhythmia

United States
Imcyse SA

Active, not recruiting

IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) (IMPACT)

Diabetes Mellitus, Type 1

United Kingdom, United States, Australia, Lithuania, Belgium, Italy, Slovenia, Sweden
Bayer

Completed

Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations (Orca)

Pharmacology, Clinical

Germany
Gilead Sciences

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

HCV Infection

United States, Netherlands, Germany
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States, France
Northwestern University
National Institute on Aging (NIA)

Recruiting

Tau PET Imaging in Atypical Dementias

Primary Progressive Aphasia With Suspected Alzheimer's Disease

United States

Search clinical trials for: Debio 1450

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations